NewAmsterdam Pharma Company N.V. NAMSW NASDAQ

NewAmsterdam Pharma Company N.V. (NAMSW) reported total assets of $769.28M and total liabilities of $85.85M for fiscal year 2025, resulting in total equity of $683.43M.

The company held $636.24M in cash and short-term investments. Total debt stood at $202K, with net debt of $-489.8M. The Debt-to-Equity (D/E) ratio was 0 (conservative).

Current ratio is 7.88, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0, current ratio of 7.88 — balance sheet is strong
• MOAT (58/100) — Total assets $769.28M and equity $683.43M support the company's competitive scale
• VALUE (100/100) — Debt-to-Equity 0 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 53/100 with 2/7 criteria passed.

NAMS

NewAmsterdam Pharma Company N.V.

$34.44

-4.99%

ROIVW

Roivant Sciences Ltd.

$2.75

+4.56%

OABIW

OmniAb, Inc.

$0.09

+0.00%

SCLXW

Scilex Holding Company

$0.10

+54.06%

GRNAW

GreenLight Biosciences Holdings

$0.02

+8.91%

LLY

Eli Lilly and Company

$922.50

-0.76%

JNJ

Johnson & Johnson

$240.10

+0.90%

ABBV

AbbVie Inc.

$210.32

+1.86%